Outcomes and Costs of Treating Hepatitis C Patients in the Era of First
Generation Protease Inhibitors – Results from the PAN Study by Stahmeyer, Jona T. et al.
RESEARCH ARTICLE
Outcomes and Costs of Treating Hepatitis C
Patients in the Era of First Generation
Protease Inhibitors – Results from the PAN
Study
Jona T. Stahmeyer1☯*, Siegbert Rossol2☯, Florian Bert2, Klaus H. W. Böker3, Harald-
Robert Bruch4, Christoph Eisenbach5, Ralph Link6, Christine John7, Stefan Mauss8,
Renate Heyne9, Eckart Schott10, Heike Pfeiffer-Vornkahl11, Dietrich Hüppe12,
Christian Krauth1
1 Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School,
Hannover, Germany, 2 Department of Internal Medicine, Krankenhaus Nordwest, Frankfurt a.M., Germany,
3 Leberpraxis, Hannover, Germany, 4 Schwerpunktpraxis Bonn, Bonn, Germany, 5 University Hospital
Heidelberg, Dept. of Gastroenterology, Heidelberg, Germany, 6 St. Josefs Hospital, Offenburg, Germany,
7 Medical Practice, Berlin, Germany, 8 Center for HIV and Hepatogastroenterology, Duesseldorf, Germany,
9 Leberzentrum am Checkpoint, Berlin, Germany, 10 Dept. of Hepatology and Gastroenterology, Charité
Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, 11 e-factum –GmbH, Butzbach,
Germany, 12 Center of Gastroenterology, Herne, Germany




Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Intro-
duction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic
response rates (SVR) in genotype 1 patients but were accompanied by higher treatment
costs and more side effects. Aim of the study was to assess outcomes and costs of treating
HCV with TVR or BOC in routine care.
2. Material and Methods
Data was obtained from a non-interventional study. This analysis relates on a subset of
1,786 patients for whom resource utilisation was documented. Sociodemografic and clinical
parameters as well as resource utilisation were collected using a web-based data recording
system. Costs were calculated using official remuneration schemes.
3. Results
Mean age of patients was 49.2 years, 58.6% were male. In treatment-naive patients SVR-
rates of 62.2% and 55.7% for TVR and BOC were observed (prior relapser: 68.5% for TVR
and 63.5% for BOC; prior non-responder: 45.6% for TVR and 39.1% for BOC). Treatment
costs are dominated by costs for pharmaceuticals and range between €39,081 and
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€53,491. We calculated average costs per SVR of €81,347 (TVR) and €70,163 (BOC) in
treatment-naive patients (prior relapser: 78,089 €/SVR for TVR and 82,077 €/SVR for BOC;
prior non-responder: 116,509 €/SVR for TVR and 110,156 €/SVR for BOC). Quality of life
data showed a considerable decrease during treatment.
4. Conclusion
Our study is one of few investigating both, outcomes and costs, of treating HCV in a real-life
setting. Data can serve as a reference in the discussion of increasing costs in recently intro-
duced agents.
Introduction
Chronic hepatitis C virus infections (HCV) cause a significant public health burden. World-
wide, about 170 million people are chronically infected with HCV [1]. Data from the German
National Health and Examination Survey (DEGS1) estimate an anti HCV-prevalence of 0.3%
in the general population [2]. More extended studies which consider a higher prevalence in
risk-groups such as drug abusers, prison inmates and some urban areas, estimated the number
of patients with a viremic infection at 275,000 (165,000–494,000) in Germany [3;4]. The major-
ity of patients have acquired genotype 1 or 3 hepatitis C virus [5]. A large part of infected
patients are unaware of their disease. Most infections remain undiagnosed until serious and
potentially lethal complications such as liver cirrhosis and hepatocellular carcinoma occur [6].
Estimates assume that about 27% of liver cirrhosis and 25% of hepatocellular carcinoma
(HCC) are attributable to chronic HCV [7]. Further, chronic hepatitis C is still the most com-
mon cause for liver transplantations [8]. The primary goal of treating hepatitis C is to eradicate
the virus (sustained viral response, SVR) and thus to reduce the morbidity and mortality of
infected patients. Recent studies have shown that SVR is associated with a decreasing risk of
liver cirrhosis, liver-related mortality and all-cause mortality as well as an increase in quality of
life [9–11].
The introduction of first generation protease inhibitors telaprevir (TVR) and boceprevir
(BOC) for the treatment of patients infected with HCV genotype 1 in 2011 has significantly
increased SVR rates while shortening treatment duration for many patients. Especially treat-
ment-experienced patients who failed to previous treatment attempts with peginterferon
(PegIFN) and ribavirin (RBV) dual therapy have benefited from these treatment options. In
2012, the Joint Federal Committee (Gemeinsamer Bundesausschuss) estimated the number of
patients eligible for treatment at 46,000 in Germany (treatment-naive: 12,000; treatment-expe-
rienced 34,000) [12;13]. From 2011 to 2014, triple therapy with TVR or BOC has been estab-
lished as the new standard of care [14]. However, triple-therapy with first generation protease
inhibitors is associated with significantly increased adverse events and patients with advanced
fibrosis or other comorbidities are often not eligible for treatment [15]. Further, treatment
options are associated with increased costs. Although several cost-effectiveness studies have
shown that treatment with TVR or BOC is cost-effective, there is still a lack of studies evaluat-
ing outcomes and costs of treating hepatitis C with TVR and BOC in a real-life setting.
A study by Bichoupan et al. (2014) showed extremely high costs of $189,000 per SVR for
patients receiving first generation protease inhibitors [16]. In another real-life study average
SVR-rates of 53% for TVR and 40% for BOC were observed [17]. Due to small sample sizes,
extensive subgroup analyses could not be conducted and generalisation of these results is
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doubtful. First interim data from the “Peginterferon alfa-2a non-interventional trial” (PAN)
cohort showed SVR-rates in treatment-naive patients of 63.4% and 55.0% for TVR and BOC,
respectively. Results were lower in treatment-experienced patients, except for patients with
prior relapse [18].
Therefore, the aim of this study was to analyse outcomes and healthcare costs of treating
patients with TVR or BOC in routine care using the largest cohort of HCV infected patients so
far. Further, information on quality of life was collected.
Methods
The data analyzed are part of the PAN trial. The PAN study is a prospective, open-label, multi-
center, non-interventional study started in 2011 and initiated by the Association of German
Gastroenterologists in Private Practice (Berufsverband Niedergelassener Gastroenterologen
Deutschlands e.V.) in cooperation with Roche Pharma AG, Germany. It is a continuation of a
non-interventional study analyzing effectiveness and treatment costs of patients receiving
peginterferon and ribavirin [19–21]. The design of the study was approved by the Ethical Com-
mittee of the Aerztekammer Westfalen-Lippe and patients gave written informed consent
before taking part in the study. Inclusion criteria were indication for therapy of chronic hepati-
tis C according to the attending physician as well as an age of 18 years or above. Federal health
authorities were infomed about the study: The trial was registered at the Association of
Researching Pharmaceutical Manufacturers (ML25724) and at ClinicalTrials.gov
(NCT01679834). Sponsor according to GCP/GEP of the non-interventional study was Roche
Pharma AG, Germany. The authors were independent from the funding institutions in data
analysis, data interpretation, report writing and publication.
A web-based data recording system was used for data collection. The quality of the data was
assessed by automated plausibility checks as well as additional on-site monitoring. Data collec-
tion included treatment outcomes (SVR), sociodemographic and clinical parameters, HCV-
associated health care utilisation and quality of life (QoL). SVR was defined as undetectable
HCV RNA at least 10 weeks after end of treatment (EoT). This definition was used because
timing of patient visits was not specified and thus some patients may not have had a physician
visit at exactly 12 or 24 weeks after end of treatment. Accordingly, patients without HCV RNA
determination 10 weeks or later after EoT or patients who were lost to follow-up were consid-
ered to have failed treatment in our analysis (intention-to-treat analysis).
Healthcare utilisation comprises outpatient care (doctor visits, laboratory testing and imag-
ing), pharmaceuticals (antiviral treatment and medication for the treatment of HCV-associated
diseases or treatment-related adverse events) as well as HCV-associated hospitalisation. Costs
of outpatient care and services are based on the German doctors’ fee scale within the statutory
health insurance scheme (Einheitlicher Bewertungsmaßstab), pharmaceutical costs were calcu-
lated using prices from the German drug directory (Rote-Liste) and hospital costs were calcu-
lated based on the German hospital reimbursement scheme (G-DRG) [22–24]. Price year was
2012.
Information on QoL was collected using the German version and transformation of the
Short-Form-36 version 2 (SF-36v2). Patients were asked to fill out the questionnaires at four
different times of treatment: (1.) baseline, (2.) treatment week 12, (3.) end of treatment, (4.) 10
to 24 weeks post treatment (SVR evaluation).
The present analysis is based on data from a defined subset of HCV-patients receiving anti-
viral treatment with TVR or BOC in combination with PegIFN and RBV and for whom
detailed information on resource utilisation was documented. Patients with HIV co-infection
and/or patients reveiving drug substitution treatment were excluded. Treatment was
Treatment Costs Hepatitis C
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recommended to be in accordance with the drug safety: SmPC (summary of product character-
istics) and national treatment guidelines but was ultimately at the discretion of the physician in
charge. In total, data on 1,786 genotype 1 patients were analysed. Data were gathered between
June 2011 and January 2014 and provided by 191 participating centers (160 outpatient prac-
tices and medical centers as well as 31 hospital-based outpatient clinics) all throughout Ger-
many and thus reflects the accepted practice of HCV-treatment in Germany.
Statistical analyses are primarily descriptive to reflect the non-interventional character of
the study. We used SPSS Statistics 12 for the analyses. Differences between subgroups were
analysed using the T-Test or χ²-Test depending in type of variable. Differences were regarded
as significant at a level of p0.05.
Results
Patient Characteristics
Overall, data on 1,786 patients receiving triple-therapy with BOC (25.3%) or TVR (74.7%)
were analysed. Mean age was 49.2 years (SD 11.2), 58.6% were male. Mean height and weight
were 172.3 cm (SD 9.4) and 79.2 kg (SD 15.3), respectively (Body-Mass-Index 26.6; SD 4.5).
Almost all patients were Caucasian. Estimated duration of infection was 16.9 years (SD 10.9)
on average. Most common routes of transmission were historical intravenous drug abuse
(19.4%), blood products (17.4%) and surgical/medical interventions (8.5%). For almost half of
the patients (49.7%) the route of transmission was unknown. About half of patients were treat-
ment-naive (44.5%), 29.8% had a relapse and 22.6% had non-response to previous therapy
with PegIFN/RBV. Other patients (2.8%) discontinued previous treatment due to adverse
events and/or personal reasons and six patients (0.3%) had a reinfection. Comorbidities were
frequent in our sample (58.9%). Most frequent diseases were cardiovascular diseases (20.5%),
psychiatric disorders (12.4%), thyroidal dysfunction (9.1%) and diabetes mellitus (7.8%). 15
patients (0.8%) were co-infected with hepatitis B virus. A history of alcohol and/or drug abuse
was observed for 18.4% of patients.
Baseline viral load was available for 1,742 patients (97.5%). Average viral load was 3.01 mil-
lion IU; 27.2% of patients had a low viral load (400,000 IU/ml) and 72.8% had a high viral
load (>400,000 IU/ml). Mean levels of AST and ALT were 67.7 U/I and 92.7 U/I, respectively.
Due to the non-interventional character of the study, no standardized evaluation on liver
fibrosis was performed. Information on liver fibrosis/cirrhosis was gathered by available infor-
mation. Most patients (79.9%) received at least one ultrasound examination of the liver; 15.8%
had a liver biopsy. Information on other methods for evaluation of liver fibrosis (e.g. FibroScan,
FibroTest or acoustic radiation force impulse) was not sufficiently documented. Further, these
methods are not covered by the statutory health insurance and have to be paid by the patients
themselves. Based on available data (e.g. biopsy, clinical appearance, sonography, elastography)
14.2% of patients were classified as cirrhotics. We further used APRI-score to determine the
degree of liver fibrosis/cirrhosis. Mean APRI-score was 1.0 (SD 1.32; n = 1,483). An APRI-
score of0.5 indicating no significant fibrosis was observed in 42.9% of patients, 39.8% had a
score>0.5 and1.5 and 17.3% had a score>1.5 indicating advanced fibrosis or liver cirrhosis.
Patient characteristics are summarized in Table 1.
Treatment response
Overall, we observed an SVR-rate of 58.2% in our total sample who received treatment with
either TVR or BOC (n = 1,786). In treatment-naive patients SVR-rates of 62.2% and 55.7%
were observed for TVR and BOC, respectively. Difference between TVR and BOC treatment
was not significant (p = 0.085, mean difference 6.5%, 95%-CI -0.9–14.0). SVR-rates in patients
Treatment Costs Hepatitis C
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with relapse to previous treatment were 68.5% in patients receiving TVR and 63.5% in patients
receiving BOC (p = 0.35, mean difference 5.0%, 95%-CI -5.3–15.4). In patients with non-
response to previous treatment SVR-rates were 45.6% in TVR and 39.1% in BOC (p = 0.33,
mean difference 6.5%, 95%-CI -5.3–18.3).
In total, 476 of 1,786 patients (26.7%) discontinued treatment with BOC or TVR. Reasons
for treatment discontinuation were insufficient virologic response, adverse events or other
non-medical reasons.
Table 1. Patient characteristics (n = 1,786, otherwise stated).
Parameter All patients (n = 1,786) TVR BOC TVR vs. BOC p-value
Age, years 49.2 49.3 49.0 n.s.
Sex, %
male 58.6 60.7 52.1 0.0013
female 41.4 39.3 47.9
Height, cm 172.3 172.5 171.7 0.0063
Weight, kg 79.2 79.0 79.8 n.s.
Body-Mass-Index 26.6 26.5 27.0 0.0397
Duration of infection, years 16.9 16.6 17.8 0.0425
Medical history
Treatment-naive 44.5 41.0 54.5 <0.001
Relapser 29.8 32.1 23.1
Non-responder 22.6 23.7 19.3
Other (incl. re-infection) 3.1 3.2 3.1
Route of transmission, %
Drug abuse 19.4 19.0 20.6 n.s.
Blood products 17.4 17.7 16.6
Medical/surgical intervention 8.5 7.9 10.0
Sexual contact 1.7 1.3 2.7
other 3.4 3.3 3.8
unknown 49.7 50.8 46.3
Frequent comorbidities, %
Cardiovascular disease 20.5 21.0 19.1 n.s.
Psychiatric disorder 12.4 11.8 14.2 n.s.
Thyroidal dysfunction 9.1 9.3 8.4 n.s.
Diabetes mellitus 7.8 8.1 6.9 n.s.
History of drug/alcohol abuse 18.4 17.5 20.8 n.s.
HBV-coinfection 0.8 0.7 1.1 n.s.
Baseline viral load, IU/ml 3,0 x 106 3,0 x 106 3,1 x 106 n.s.
Baseline viral load, % (n = 1,742)
 400,000 IU/ml 27.2 26.7 28.6 n.s.
> 400,000 IU/ml 72.8 73.3 71.4
AST, U/l 67.7 69.4 62.8 0.0106
ALT, U/l 92.7 95.5 84.5 n.s.
APRI-score at baseline (n = 1,483) 1.0 1.1 0.9 0.0122
APRI-score at baseline categorized, % (n = 1,483)
 0.5 42.9 42.3 44.8 n.s.
> 0.5 and 1.5 39.8 39.2 41.5
> 1.5 17.3 18.5 13.7
doi:10.1371/journal.pone.0159976.t001
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Average treatment duration in treatment-naive patients was 27.2 weeks in TVR and 31.7
weeks in BOC. 49.8% of treatment-naive patients received TVR for about 24 weeks and 18.8%
for about 48 weeks. In patients receiving BOC 52.0% received treatment for about 28 weeks
and 24.0% for 48 weeks. In treatment-experienced patients treatment durations were 31.6
weeks (38.5% received treatment for about 24 weeks and 35.7% for about 48 weeks) and 41.2
weeks (11.5% received treatment for about 28 weeks and 70.2% for about 48 weeks) in patients
with prior relapse and 33.0 weeks (11.4% received treatment for about 24 weeks and 45.8% for
about 48 weeks) and 34.7 weeks (10.3% received treatment for about 28 weeks and 51.7% for
about 48 weeks) in patients with prior non-response for TVR and BOC, respectively. Informa-
tion on response rates and treatment duration are summarized in Table 2. Shorter treatment
duration in BOC patients with prior non-response compared to prior relapsers is due to more
frequent treatment discontinuations.
Adverse events
Adverse events (AE) were common in patients receiving TVR or BOC treatment. 90.5% of
patients had at least one non-serious AE. Most common non-serious AEs were fatigue (62.9%),
skin diseases (35.9%), pruritus (31.2%), nausea (25.8%), anemia (25.6%), headache (22.3%),
arthralgia (17.7%), sleeplessness (16.2%), depressive mood (14.4%) and fever (13.4%).
Serious adverse events were observed in 11.2% of treated patients. Most frequent SAEs were
anemia (42 patients; 2.4%), rash (14 patients; 0.8%), pancytopenia (10 patients; 0.6%), fever (7
patients, 0.4%) and sepsis (7 patients, 0.4%). 4.3%% (TVR) and 0.9% (BOC) of patients discon-
tinued therapy due to adverse events.
Resource utilisation and costs
On average, patients had 12.1 doctor visits. However, patients receiving treatment with TVR
had less doctor visits compared to BOC patients (11.7 vs. 13.3; p<0.0001). Besides antiviral
treatment with either TVR or BOC, nearly all patients (93.5%) received co-medication for the
treatment of HCV-associated diseases or therapy related side effects. 100 patients (5.6%)
needed to be treated as inpatients due to their HCV-infection or therapy related side effects.
Average length of inpatient care was 4.8 days.
Table 2. Treatment outcomes by patient group.
Treatment outcome




No SVR,% (Patients with treatment discontinuation due to non-
response or AEs or personal reasons and patients with relapse)
Lost to follow-up,
not tested,%
Treatment-naive 794 28.6 60.2 29.3 10.5
TVR 548 27.2 62.2 29.2 8.6
BOC 246 31.7 55.7 29.7 14.6
Treatment-
experienced
Prior Relapser 533 33.5 67.5 25.4 7.1
TVR 429 31.6 68.5 25.0 6.5
BOC 104 41.2 63.5 25.9 9.6
Prior Non-
Responder
403 33.3 44.2 49.3 6.5
TVR 316 33.0 45.6 48.1 6.3
BOC 87 34.7 39.1 54.0 6.9
doi:10.1371/journal.pone.0159976.t002
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Calculation of treatment costs is based on 1,784 patients as complete resource utilisation
data were not available for two patients (one TVR and one BOC). The costs for ambulatory
care amount for €1,098 on average (TVR: €1,071; BOC: €1,179). These include costs for doctor
visits, laboratory services and imaging techniques which are necessary for initiating antiviral
treatment as well as treatment monitoring. Average pharmaceutical costs were €48,562 and
contain antiviral treatment with TVR or BOC with PegIFN and RBV (€48,549) and costs for
co-medication (€13). Antiviral treatment costs were higher in patients receiving triple-therapy
with TVR (€50,862) compared to BOC patients (€41,693). Average costs for co-medication
were almost identical (TVR: €13; BOC: €14). Mean costs for inpatient care were €165 for the
total population (TVR: €188; BOC: €99). Average costs in 100 patients who were treated as
inpatients were €2,946 (TVR: €2,979; BOC: €2,778). Total treatment costs sum up for €49,826
(TVR: €52,120; BOC: €42,970). Further, costs were stratified by treatment status (Table 3).
Costs per SVR
Based on SVR-rates and cost estimates in different patient groups we determined how much
money has to be spent to achieve SVR in one person with HCV. In treatment-naive patients
average costs were 81,347 €/SVR for patients receiving TVR and 70,163 €/SVR for patients
treated with BOC. Average costs per SVR in patients with relapse to prior treatment were
€78,089 and €82,077 for TVR and BOC, respectively. In patients with non-response to previous
treatment average costs were 116,509 €/SVR (TVR) and 110,156 €/SVR (BOC). Costs per SVR
estimates are summarized in Table 4.
Table 3. Treatment costs by patient group.
Costs, €
Patient group n Number of doctor visits Ambulatory care Pharmaceuticals Inpatient care Total
Treatment-naive
TVR 548 11.2 1,026 49,439 133 50,598
BOC 246 12.5 1,119 37,843 119 39,081
Treatment-experienced
Prior Relapser
TVR 429 11.7 1,087 52,150 254 53,491
BOC 103 15.3 1,334 50,766 119 52,119
Prior Non-Responder
TVR 316 12.8 1,123 51,804 201 53,128
BOC 87 13.8 1,171 41,866 34 43,071
doi:10.1371/journal.pone.0159976.t003
Table 4. Costs per SVR for patient groups.
Patient group n SVR, % Treatment costs, € Costs per SVR, €
Treatment-naive
TVR 548 62.2 50,598 81,347
BOC 246 55.7 39,081 70,163
Treatment-experienced
Prior Relapser
TVR 429 68.5 53,491 78,089
BOC 103 63.5 52,119 82,077
Prior Non-Responder
TVR 316 45.6 53,128 116,509
BOC 87 39.1 43,071 110,156
doi:10.1371/journal.pone.0159976.t004
Treatment Costs Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0159976 July 28, 2016 7 / 14
Quality of life
Complete information on quality of life was not available for the total study population as
some patients did not fill out the questionnaires at all or did not fill out questionnaires regu-
larly. Therefore, we used three different sub-samples to conduct quality of life analyses and to
use all patients available:
1. Quality of life of infected patients (baseline analysis)
2. Development of quality of life during treatment (complete data analysis)
3. Differences in quality of life depending on SVR (10 weeks or later post treatment analysis)
Complete data on QoL at baseline were available for 422 patients. The analysis supports the
evidence that chronic HCV infection is associated with reduced QoL compared to QoL in the
general population. Biggest QoL restrictions were observed for general health (-19%), vitality
(-19%) and role-emotional (-15%). All SF-36 QoL subscales showed significantly lower values,
except for bodily pain. Further, QoL sumscores were significantly lower compared to general
population (Table 5).
To analyse the reduction as well as the development of quality of life during antiviral treat-
ment all patients who participated in all surveys (baseline, treatment week 12, end of treatment,
24 weeks post treatment) were analyzed (n = 316). The analysis shows a significant decrease in
quality of life during treatment (baseline vs. treatment week 12) for all SF-36 scales, whereas
decrease is greatest in role-physical (-52.0%), vitality (-43.6%) and role-emotional (-40.5%).
Development of quality of life is described in Fig 1. At the end of treatment QoL increases.
Detailed information on QoL stratified for TVR and BOC is presented in the appendix. Post
treatment QoL scales show higher or equal values compared to baseline. A comparison of
patients who achieved SVR and patients who failed treatment demonstrates that achievement
of SVR is associated with an increased QoL. All SF-36 subscales, except role-physical and
bodily pain, show higher values (Table 6).
Discussion
We evaluated outcomes and costs of treating genotype 1 patients with first generation protease
inhibitors TVR and BOC in a real-life setting using data from the German Hepatitis C Registry.
Data on 1,786 patients was provided by 191 outpatient practices and hospital outpatient
Table 5. Quality of life at baseline.
HCV-patients German norm population
SF-36 scales Mean SD n Mean SD Diff p-value
Physical functioning 81 22.8 432 86 22.3 4.6 <0.0001
Role—physical 73 38.2 431 83 32.6 10.0 <0.0001
Bodily pain 80 25.7 433 79 27.4 -0.9 0.5107
General health 57 19.9 430 68 20.3 10.9 <0.0001
Vitality 53 21.8 430 63 18.5 10.2 <0.0001
Social functioning 79 22.8 433 89 18.4 9.8 <0.0001
Role—emotional 78 37.2 427 90 26.3 12.0 <0.0001
Mental health 68 18.5 430 74 16.6 5.8 <0.0001
Sumscores:
Physical component summary score 49 9.1 422 50 10.3 1.1 0.0459
Mental component summary score 44 12.3 422 51 8.2 7.4 0.0001
doi:10.1371/journal.pone.0159976.t005
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Fig 1. QoL development during treatment.
doi:10.1371/journal.pone.0159976.g001
Treatment Costs Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0159976 July 28, 2016 9 / 14
departments throughout Germany using a web-based data recording system. To our knowl-
edge, this is the largest real-life cohort of patients receiving first generation protease inhibitors
TVR or BOC so far.
We observed SVR-rates of 62.2% for TVR and 55.7% for BOC in treatment-naive patients
and thus confirm results from an interim analysis with a smaller patient sample [18]. These
rates are considerably lower than rates observed in clinical trials (TVR: 75%; BOC: 66%)
[25;26]. Similar results were shown for treatment-experienced patients [27;28]. In total, 153
patients (8.6%) were lost to follow-up or not tested. These findings are frequently observed as
clinical trial populations usually do not reflect the population treated in routine care. Further-
more, treatment monitoring is more frequent and compliance is encouraged more intensely
and treatment discontinuations are less frequent due to strict study protocols. Therefore,
higher rates of lost to follow-up patients are not unusual in real-life settings.
Another US study by Backus et al. (2014) evaluated outcomes of TVR and BOC treatment
in a cohort of HCV-infected veterans. SVR-rates did not significantly differ between both treat-
ments in the total cohort (TVR: 52%, BOC: 50%, p = 0.72) as well as subgroups. Outcome in
treatment-naive patients were 55% and 53% for TVR and BOC, respectively. Lower SVR-rates
were observed for treatment-experienced patients, except for patients with prior relapse. Fur-
ther, patients with cirrhosis were less likely to achieve SVR [29].
Two other studies by Vo et al. (2015) and Wehmeyer et al. (2014) confirm these results and
prove that results from clinical trials could not be easily reproduced in routine care [17;30]. Vo
et al. showed SVR-rates of 53% for TVR and 40% for BOC.[17] Wehmeyer et al. observed a
SVR-rate of 60.8% whereas no significant differences between TVR and BOC were observed
[30]. Both analyses confirm lower SVR-rates in patients with cirrhosis.
In treatment-naive patients average treatment costs of €50,598 for TVR and €39,081 for
BOC were observed. In treatment-experienced patients average treatment costs were slightly
higher. We estimated average costs per SVR of €81,347 for TVR and €70,163 for BOC in treat-
ment-naive patients. In treatment-experienced patients costs per SVR were about €80,000 in
prior relapse for both TVR and BOC. In prior non-responder costs were 116,509 €/SVR and
110,156 €/SVR for TVR and BOC, respectively.
A study by Bichoupan et al. (2014) showed median treatment costs per SVR of $189,338 for
patients receiving antiviral treatment with TVR in the United States [16]. These data should be
interpreted with caution as 35% of patients had advanced fibrosis/cirrhosis and 73% had
received dual therapy with PegIFN and RBV in the past. Median treatment costs were $83,721
Table 6. Post treatment QoL—SVR vs. no SVR.
No SVR (n = 106) SVR (n = 378) No SVR vs. SVR Total (n = 484)
SF-36 scales Mean SD Mean SD p-value Mean SD
Physical functioning 81 20.7 86 21.4 0.0328 85 21.3
Role—physical 76 37.4 82 34.2 0.1187 80 34.9
Bodily pain 81 23.4 85 23.1 0.1168 84 23.2
General health 54 20.8 67 20.5 0.0001 64 21.2
Vitality 53 20.8 63 20.4 0.0001 61 20.8
Social functioning 75 24.6 83 21.9 0.0013 81 22.7
Role—emotional 75 41.4 84 33.8 0.0218 82 35.7
Mental health 66 18.7 72 18.7 0.0037 71 18.9
Sumscores:
Physical component summary score 49 8.6 51 8.2 0.0286 51 8.3
Mental component summary score 42 13.5 47 11.9 0.0001 46 12.5
doi:10.1371/journal.pone.0159976.t006
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and only 44% of patients achieved SVR. Subgroup analyses showed higher costs and lower
SVR rates in treatment-experienced patients and patients with advanced fibrosis/cirrhosis [16].
Compared to real-life treatment outcomes and costs in genotype 1 patients receiving dual
therapy with PegIFN and RBV, our analysis shows higher costs per SVR.[19] Average costs per
SVR in dual treatment were €44,744 in treatment-naive patients, €73,816 in patients with prior
relapse and €81,796 in patients with prior non-response. Furthermore, the decrease of QoL
during treatment was greater in patients receiving TVR or BOC compared to dual treatment
with PegIFN and RBV [19].
Therefore, this analysis supports the findings from previous studies and demonstrates that
triple therapy with TVR or BOC is associated with a significant reduction in QoL mostly due to
therapy-related side effects/adverse events. Further, we could show that the achievement of
SVR is associated with an increase in QoL.
Long-term cost effectiveness of TVR and BOC treatment including costs of disease progres-
sion in patients who do not achieve SVR in respective treatments have been comprehensively
evaluated in different countries (e.g. USA, Italy, UK, Germany) [31–37]. These analyses show
that TVR and BOC could be considered as cost-effective. Model results are mainly influenced
by the discount rate, SVR-rates and treatment costs [31–37].
A major limitation of our study is that patients were not randomly assigned to participate.
Patients were recruited by study centers based on availability and their willingness to partici-
pate. This could lead to a response bias. However, potential bias could be regarded as low due
to the large patient sample. Although healthcare utilisation was collected timely by filling out
standardized form in the web-based recording system, missing data (e.g. medical specialist vis-
its) might lead to an underestimation of actual costs. As major cost drivers are HCV-medica-
tion and HCV-related diagnostics, the impact of missing data is low. Results are based on a
homogeneous population consisting of Caucasian patients. Therefore, transferability of results
to other countries may be limited. However, the strengths of our study are comprehensive
information on patient characteristics, a data quality assurance system and a large patient sam-
ple provided by a large number of study centers throughout Germany reflecting routine care in
daily practice.
Recent developments in treating HCV have increased SVR-rates in all HCV genotypes,
shortened treatment duration and lead to a favorable side effect profile. These new DAAs allow
treating patients with prior contraindication for antiviral treatment due to interferon intoler-
ance, advanced stages of liver disease, older age or comorbidities. In treatment-naive genotype
1 patients, treatment with sofosbuvir/ledipasvir (SOF/LDV) with or without RBV or combina-
tion treatment with paritaprevir/ritonavir/ombitasvir/dasabuvir (PTV/r/OMV/DSV) with or
without RBV results in SVR-rates above 95% [38–42]. High SVR-rates were also achieved in
treatment-experienced genotype 1 patients as well as in other genotypes [43;44]. These
advances in HCV-treatment were accompanied by a further increase in treatment costs and
have raised the question, whether such high prices are affordable [45–47]. For example, weekly
costs of new agents are $8,750 for SOF/LDV, $7,000 for SOF, $6,943 for PTV/r/OMV/DSV in
the United States. Due to high costs several European countries have delayed the introduction
of new DAAs and restricted the use for patients with advanced liver disease [48–50]. Despite
high prices, new DAA regimens SOF/LDV and PTV/r/OMV/DSV seem to be cost-effective
considering national or international accepted willingness-to-pay thresholds [51–54]. Due to
significant differences in health systems, structures of healthcare provision and costs between
countries, transferability of economic evaluation results is limited [55]. Therefore, there is high
need for national health economic evaluation results from real-life studies as well as short and
long-term modelling studies.
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Summarizing the results of our study, we estimated average costs of hepatitis C triple-ther-
apy with TVR or BOC therapy in clinical practice ranging between €39,081 in treatment-naive
patients receiving BOC and €53,491 in treatment-experienced patients (relapser) receiving
TVR. Costs per SVR in treatment-naive patients were €81,347 and €70,163 for TVR and BOC,
respectively. Highest costs per SVR were observed in patients with non-response to prior treat-
ment (TVR: €116,509; BOC €110,156). Further, insights on QoL of HCV-infected patients
were described. Therefore, these data can set a basis for a comparison with newly introduced
DAA regimens and help to objectify the current discussion concerning high prices for HCV
medication.
Author Contributions
Conceived and designed the experiments: JTS SR CK. Performed the experiments: SR FB
KHWB HRB CE RL CJ SM RH ES DH. Analyzed the data: JTS SR HPV CK. Wrote the paper:
JTS SR CK. Data Management: HPV. Statistical analyses: JTS HPV.
References
1. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C
infection. Geneva; 2014.
2. Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. [Epidemiology of
hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examina-
tion Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
2013; 56(5–6):707–15. doi: 10.1007/s00103-013-1673-x PMID: 23703489
3. Vermehren J, Schlosser B, Domke D, Elanjimattom S, Muller C, Hintereder G, et al. High prevalence of
anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening
analysis of 28,809 patients. PLoS One 2012; 7(7):e41206. doi: 10.1371/journal.pone.0041206 PMID:
22848445
4. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical
epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 Suppl 1:5–33. doi:
10.1111/jvh.12247 PMID: 24713004
5. Huppe D, Zehnter E, Mauss S, Boker K, Lutz T, Racky S, et al. [Epidemiology of chronic hepatitis C in
Germany—an analysis of 10,326 patients in hepatitis centres and outpatient units]. Z Gastroenterol
2008; 46(1):34–44. doi: 10.1055/s-2007-963691 PMID: 18188814
6. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology
2014; 146(5):1176–92. doi: 10.1053/j.gastro.2014.03.003 PMID: 24631495
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hep-
atitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4):529–38.
PMID: 16879891
8. Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B, Clavien PA. Challenges to liver transplantation
and strategies to improve outcomes. Gastroenterology 2015; 148(2):307–23. doi: 10.1053/j.gastro.
2014.08.045 PMID: 25224524
9. Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, et al. Toward a more complete
understanding of the association between a hepatitis C sustained viral response and cause-specific
outcomes. Hepatology 2015; 62(2):355–64. doi: 10.1002/hep.27766 PMID: 25716707
10. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between
sustained virological response and all-cause mortality among patients with chronic hepatitis C and
advanced hepatic fibrosis. JAMA 2012; 308(24):2584–93. doi: 10.1001/jama.2012.144878 PMID:
23268517
11. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral ther-
apy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 2012; 57(5):946–52. doi: 10.
1016/j.jhep.2012.06.030 PMID: 22760009
12. Bundesausschuss Gemeinsamen. Bekanntmachung eines Beschlusses des Gemeinsamen Bunde-
sausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII—Beschlüsse über
die Nutzenbewertung von Arzneimitteln mit neuenWirkstoffen nach §35a des Fünften Buches Sozial-
gesetzbuch (SGB V) Boceprevir. Bundesanzeiger 2012;52:1269.
Treatment Costs Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0159976 July 28, 2016 12 / 14
13. Bundesausschuss Gemeinsamer. Bekanntmachung eines Beschlusses des Gemeinsamen Bunde-
sausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII—Beschlüsse über
die Nutzenbewertung von Arzneimitteln mit neuenWirkstoffen nach § 35a des Fünften Buches Sozial-
gesetzbuch (SGB V) Telaprevir. Bundesanzeiger 2012.
14. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 349:g3308.
15. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, et al. Eligibility and
safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
PLoS One 2013; 8(2):e55285. doi: 10.1371/journal.pone.0055285 PMID: 23383319
16. Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, et al. Costs of telaprevir-
based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 2014; 60
(4):1187–95. doi: 10.1002/hep.27340 PMID: 25065814
17. Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, et al. Poor Sustained Virological Response
in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and
Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci 2015; 60(4):1045–51. doi: 10.1007/s10620-015-
3621-0 PMID: 25821099
18. Mauss S, Boker K, Buggisch P, Christensen S, HofmannWP, Schott E, et al. Real-life experience with
first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN
cohort. Z Gastroenterol 2015; 53(7):644–54. doi: 10.1055/s-0034-1399383 PMID: 26167694
19. Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Huppe D, et al. Costs and outcomes of
treating chronic hepatitis C patients in routine care—results from a nationwide multicenter trial. J Viral
Hepat 2016; 23(2):105–15. doi: 10.1111/jvh.12471 PMID: 26411532
20. HofmannWP, Mauss S, Lutz T, Schober A, Boker K, Moog G, et al. Benefit of Treatment Individualiza-
tion in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Non-
interventional Cohort Study. PLoS One 2015; 10(7):e0134839. doi: 10.1371/journal.pone.0134839
PMID: 26230998
21. Mauss S, Boker K, Buggisch P, Christensen S, HofmannWP, Schott E, et al. Real-life experience with
first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN
cohort. Z Gastroenterol 2015; 53(7):644–54. doi: 10.1055/s-0034-1399383 PMID: 26167694
22. Bundesvereinigung Kassenärztliche. Einheitlicher Bewertungsmaßstab (EBM). 2012.
23. Rote Liste1 Service GmbH. ROTE LISTE1-Online. 2012.
24. InEK—Institut für Entgeldsystem im Krankenhaus. G-DRG-Fallpauschalen-Katalog 2012. 2012.
25. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir
for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25):2405–16. doi:
10.1056/NEJMoa1012912 PMID: 21696307
26. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated
chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1195–206. doi: 10.1056/
NEJMoa1010494 PMID: 21449783
27. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously
treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1207–17. doi: 10.1056/
NEJMoa1009482 PMID: 21449784
28. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV
infection. N Engl J Med 2011; 364(25):2417–28. doi: 10.1056/NEJMoa1013086 PMID: 21696308
29. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepati-
tis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther
2014; 39(1):93–103. doi: 10.1111/apt.12546 PMID: 24206566
30. Wehmeyer MH, Eissing F, Jordan S, Roder C, Hennigs A, Degen O, et al. Safety and efficacy of prote-
ase inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic
hepatitis C genotype 1 infection. BMCGastroenterol 2014; 14:87. doi: 10.1186/1471-230X-14-87
PMID: 24884400
31. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or tel-
aprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56(3):850–60. doi:
10.1002/hep.25734 PMID: 22454336
32. Camma C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, et al. Cost-effectiveness of boceprevir or
telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol 2013; 59
(4):658–66. doi: 10.1016/j.jhep.2013.05.019 PMID: 23707373
33. Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-effectiveness of
boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United
States. Value Health 2013; 16(6):973–86. doi: 10.1016/j.jval.2013.07.006 PMID: 24041347
Treatment Costs Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0159976 July 28, 2016 13 / 14
34. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination
with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1
patients. J Med Econ 2014; 17(1):65–76. doi: 10.3111/13696998.2013.860033 PMID: 24160335
35. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination
with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1
patients. J Med Econ 2014; 17(1):77–87. doi: 10.3111/13696998.2013.844159 PMID: 24032626
36. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treat-
ment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156(4):279–90. doi:
10.7326/0003-4819-156-4-201202210-00005 PMID: 22351713
37. Stahmeyer JT, Schauer S, Rossol S, Wedemeyer H, Wirth D, Bianic F, et al. Cost-effectiveness of Tri-
ple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany. Journal of Health Eco-
nomics and Outcomes Research 2013; 1(3):239–53.
38. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabu-
vir with or without ribavirin for HCV. N Engl J Med 2014; 370(21):1983–92. doi: 10.1056/
NEJMoa1402338 PMID: 24795200
39. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated
HCV genotype 1 infection. N Engl J Med 2014; 370(20):1889–98. doi: 10.1056/NEJMoa1402454
PMID: 24725239
40. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbu-
vir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370(20):1879–88. doi: 10.
1056/NEJMoa1402355 PMID: 24720702
41. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-
450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17):1594–603. doi: 10.1056/
NEJMoa1315722 PMID: 24720703
42. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and
dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21):1973–82. doi: 10.
1056/NEJMoa1402869 PMID: 24725237
43. EASL. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63(1):199–236.
doi: 10.1016/j.jhep.2015.03.025 PMID: 25911336
44. AASLD. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating
adults infected with hepatitis C virus. Hepatology 2015; 62(3):932–54. doi: 10.1002/hep.27950 PMID:
26111063
45. Hoofnagle JH, Sherker AH. Therapy for hepatitis C—the costs of success. N Engl J Med 2014; 370
(16):1552–3. doi: 10.1056/NEJMe1401508 PMID: 24725236
46. Cohen J. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure. Science 2013; 342
(6164):1302–3. doi: 10.1126/science.342.6164.1302 PMID: 24337268
47. Stahmeyer JT, Rossol S, Krauth C. Outcomes, costs and cost-effectiveness of treating hepatitis C with
direct acting antivirals. J Comp Eff Res 2015;1–11.
48. Boseley S. Hepatitis C drug delayed by NHS due to high cost. The Guardian. 16-1-2015.
49. Santi P. Hépatite C: le nouveau hold-up des labos. Le Monde 8-7-2014.
50. Hepatitis C patients stage sit-in to demand access to new treatment. El Pais 19-12-2014.
51. Najafzadeh M, Andersson K, ShrankWH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness
of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015; 162(6):407–19. doi: 10.
7326/M14-1152 PMID: 25775313
52. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledi-
pasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Phar-
macol Ther 2015; 41(6):544–63. doi: 10.1111/apt.13081 PMID: 25619871
53. Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepati-
tis C in the US. BMCGastroenterol 2015; 15:98. doi: 10.1186/s12876-015-0320-4 PMID: 26239358
54. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C
virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162(6):397–
406. doi: 10.7326/M14-1336 PMID: 25775312
55. DrummondM, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations
across jurisdictions: ISPORGood Research Practices Task Force report. Value Health 2009; 12
(4):409–18. doi: 10.1111/j.1524-4733.2008.00489.x PMID: 19900249
Treatment Costs Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0159976 July 28, 2016 14 / 14
